高级别浆液性卵巢癌中CAR-T靶抗原共表达模式
研究探讨高级别浆液性卵巢癌(HGSC)中CA125、间皮素(MSLN)和叶酸受体α(FOLRA)在单个肿瘤细胞上的共表达,以指导CAR-T联合抗原靶向策略。结果显示CA125和/或MSLN(OR逻辑门控)在51.9%的病例中覆盖≥90%肿瘤细胞,而两者共表达(AND门控)仅5.8%。复发肿瘤保留三种抗原表达且TIL密度增加,支持OR门控CAR-T策略。
要点
- CA125和/或MSLN的OR门控可覆盖多数病例的绝大多数肿瘤细胞。
- CA125与MSLN共表达(AND门控)仅见于少数病例。
- 复发肿瘤保留靶抗原表达且T细胞浸润增加,利于该策略。
核心结论
- 针对CA125和MSLN的OR门控CAR-T策略可靶向多数病例中的大部分肿瘤细胞。
- 原发和复发疾病中抗原表达及T细胞浸润模式对该策略有利。
研究设计与样本
- 利用TCGA(HGSC)和GTEx(健康组织)数据库评估CA125、MSLN和FOLR1的RNA表达。
- 通过多重免疫荧光和免疫组化评估原发和复发HGSC的抗原表达谱及CD3+、CD8+、CD20+肿瘤浸润淋巴细胞(TIL)模式。
主要发现
- 转录水平上每种抗原在>90%病例中过表达,但MSLN和FOLR1在健康组织中有大量表达。
- 蛋白水平上CA125在最高比例病例和每例最多肿瘤细胞中表达,其次为MSLN和FOLRA。
- CA125和/或MSLN(OR门控)在51.9%病例中包含≥90%肿瘤细胞表达一种或两种抗原。
- 仅5.8%病例中包含≥90%肿瘤细胞共表达CA125和MSLN(AND门控)。
- 抗原表达模式与TIL呈适度相关;复发肿瘤保留所有三种抗原表达并显示TIL密度增加。
临床怎么用
- 支持优先开发针对CA125和MSLN的OR门控CAR-T细胞策略用于HGSC。
- 原发和复发肿瘤均适合该策略,复发时T细胞浸润增加可能增强疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chimeric antigen receptor (CAR)-T cell strategies ideally target a surface antigen that is exclusively and uniformly expressed by tumors; however, no such antigen is known for high-grade serous ovarian carcinoma (HGSC). A potential solution involves combinatorial antigen targeting with AND or OR logic-gating. Therefore, we investigated co-expression of CA125, Mesothelin (MSLN) and Folate Receptor alpha (FOLRA) on individual tumor cells in HGSC. METHODS: RNA expression of CA125, MSLN, and FOLR1 was assessed using TCGA (HGSC) and GTEx (healthy tissues) databases. Antigen expression profiles and CD3+, CD8+ and CD20+ tumor-infiltrating lymphocyte (TIL) patterns were assessed in primary and recurrent HGSC by multiplex immunofluorescence and immunohistochemistry. RESULTS: At the transcriptional level, each antigen was overexpressed in >90% of cases; however, MSLN and FOLR1 showed substantial expression in healthy tissues. At the protein level, CA125 was expressed by the highest proportion of cases and tumor cells per case, followed by MSLN and FOLRA. The most promising pairwise combination was CA125 and/or MSLN (OR gate), with 51.9% of cases containing ≥90% of tumor cells expressing one or both antigens. In contrast, only 5.8% of cases contained ≥90% of tumor cells co-expressing CA125 and MSLN (AND gate). Antigen expression patterns showed modest correlations with TIL. Recurrent tumors retained expression of all three antigens and showed increased TIL densities. CONCLUSIONS: An OR-gated CAR-T cell strategy against CA125 and MSLN would target the majority of tumor cells in most cases. Antigen expression and T-cell infiltration patterns are favorable for this strategy in primary and recurrent disease.
引用
- Banville AC, Wouters MCA, Oberg AL, et al. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. Gynecol Oncol. 2020. PMID: 33342620. doi:10.1016/j.ygyno.2020.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。